

arGEN-X to present at Jefferies 2015 Global Healthcare Conference on Tuesday, 2 June at 8:00 am EDT

Breda, the Netherlands / Ghent, Belgium, 1 June 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present a corporate update at the Jefferies 2015 Global Healthcare Conference in New York City (NY, USA) on Tuesday, 2 June 2015 at 8:00 am EDT.

The presentation will be **webcast live** and can be accessed on the day via [this link](#). A replay of the webcast will be available on the Company's website, under the [Reports & Presentations](#) section, for 90 days following the presentation. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

About arGEN-X

arGEN-X (ARGX) combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for longer duration of effect and greater efficacy. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey.

www.argen-x.com

For further information, please contact:

Joke Comijn, Corporate Communications Manager

+32 (0)9 243 40 70

info@arGEN-X.com

Mark Swallow/David Dible

Citigate Dewe Rogerson

+44 207 282 2948

arGEN-X@citigatedr.co.uk

Beth DelGiacco (US IR)

Stern Investor Relations

+1 212 362 1200

beth@sternir.com

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements arGEN-X makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. arGEN-X' actual results may differ materially from those predicted by the forward-looking statements. arGEN-X undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. "Management's Discussion and Analysis of Financial Condition and Results of Operations"